Drugs / rHMPV-Pa
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01255410 | Jan 2011 → Oct 2014 | Paramyxoviridae infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rHMPV-Pa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01255410 ↗ |
| Modality | Vaccine | “live-attenuated, intranasally administered HMPV vaccine” NCT01255410 ↗ |
| Route | Intranasal | “Single dose of 10\^6 PFU rHMPV-Pa vaccine delivered intranasally” NCT01255410 ↗ |